Goal and Learning Outcomes

After completing this activity, the participant should be better able to:

  • Identify the numerous clinical factors when determining a therapeutic plan for your patient with hemophilia A
  • Evaluate the mechanisms, safety, and efficacy of currently available products for bleeding prophylaxis in patients with severe hemophilia A
  • Summarize the best practices when managing patients with hemophilia A with inhibitors


Stacy E. Croteau, MD, MMS

Director Hemophilia/VWD program, Boston Children's Hospital
Medical Director, Boston Hemophilia Center
Assistant Professor of Pediatrics, Harvard Medical School

Steven Pipe, MD

Professor of Pediatrics and Pathology
Laurence A. Boxer Research Professor of Pediatrics and Communicable Diseases
Pediatric Medical Director, Hemophilia and Coagulation Disorders Program
Director, Special Coagulation Laboratory
University of Michigan


Hematology Pediatric Nurse Practitioner for the Comprehensive Bleeding Disorder Center
Children's Healthcare of Atlanta

Accreditation Information

This course is being provided by a Relias LLC strategic partner.  Consumption of this course will take place on the partners site and courses provided in this manner are not accredited by Relias LLC.